Sugammadex Versus Neostigmine in Return to Intended Oncological Therapy After Gastrointestinal Cancer Surgery: A Retrospective Study
Recommended Citation
Cortes-Mejia NA, Guerra-Londono JJ, Islam T, Lillemoe HA, Ovsak G, Feng L, and Cata JP. Sugammadex Versus Neostigmine in Return to Intended Oncological Therapy After Gastrointestinal Cancer Surgery: A Retrospective Study. Cancers (Basel) 2025;17(21).
Document Type
Article
Publication Date
11-2-2025
Publication Title
Cancers (Basel)
Keywords
neostigmine; return-to-oncological therapy; sugammadex
Abstract
Background: Adjuvant therapies improve disease-free and cancer-specific survival in digestive tract malignancies. Return to intended oncological therapy (RIOT) measures how promptly patients resume these treatments after cancer resection. Because sugammadex has demonstrated superior postoperative outcomes compared to neostigmine, we hypothesize that its use may increase the likelihood and timeliness of RIOT in patients undergoing digestive tract cancer surgery.
Methods: Adults (≥18 years) undergoing gastrointestinal, hepatobiliary cancer resection, or liver resection for limited metastases between January 2016 and December 2017 were retrospectively analyzed. Patients were grouped by neuromuscular blockade reversal agent (neostigmine vs. sugammadex). The primary outcome was RIOT within 90 days; secondary outcomes included RIOT within 180 days, time-to-RIOT, hospital length of stay, ICU admission, and readmissions.
Results: Of 4358 records screened, 1081 met the inclusion criteria: 273 (25.2%) patients with neostigmine and 808 (74.8%) with sugammadex. Patients in the neostigmine group were slightly younger, and racial distribution differed modestly, but sex, BMI, ASA class, comorbidity, cancer type, and stage were comparable. Median reversal doses were 5 mg and 200 mg, respectively. Anesthesia duration, hospital and ICU length of stay, readmissions, and ICU use showed no significant differences. RIOT frequency was also similar across groups, except for modestly higher radiotherapy resumption with neostigmine at 90 and 180 days. Overall, perioperative and oncological outcomes were largely comparable between groups.
Conclusions: Sugammadex and neostigmine showed similar RIOT rates, with only a modest difference in radiotherapy resumption. Larger studies are needed to elucidate the potential benefits of sugammadex, particularly regarding long-term oncological outcomes and treatment continuity.
PubMed ID
41228345
Volume
17
Issue
21
